Clinical Trial: Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

This study is not yet open for patient recruitment.
Verified by Children''''s Hospital and Regional Medical Center, Seattle October 2005

Sponsors and Collaborators: Children''''s Hospital and Regional Medical Center, Seattle
sanofi pasteur
Information provided by: Children''''s Hospital and Regional Medical Center, Seattle Identifier: NCT00242424


Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age. Infants will receive inactivated influenza vaccine at the same time as other vaccines on the routine immunization schedule. Infants will be randomized at enrollment to receive inactivated influenza vaccine or placebo at a 2:1 ratio. This study is double-blind, randomized, and placebo-controlled.
Condition Intervention Phase
Inactivated Influenza Vaccine
 Vaccine: 2005-2006 trivalent inactivated influenza vaccine
Phase II

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Bio-equivalence Study

Official Title: Safety and Immunogenicity of Fluzone Influenza Virus Vaccine (2005-2006 Formulation) Among Healthy Children 6 to 12 Weeks of Age

Further study details as provided by Children''''s Hospital and Regional Medical Center, Seattle:
Primary Outcomes: To demonstrate the safety of Fluzone vaccine administered to 2-month old children
Secondary Outcomes: There are no secondary endpoints, but other observational objectives that will be evaluated include immunogenicity of trivalent inactivated influenza vaccines in infants administered inactivated influenza vaccine at 2 and 3 months of age, and serological
Expected Total Enrollment:  1380

Study start: September 2005


Ages Eligible for Study:  42 Days   -   84 Days,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers


Inclusion Criteria:

  • Age 42 to 84 days on the day of inclusion
  • Full term (born at >=36 weeks with birth weight >=2.5 kg
  • Considered to be in good health
  • Parental consent obtained and available
  • Available for the study duration (6 months)

Exclusion Criteria:

  • Reported allergy to egg proteins, chicken proteins
  • Previous history of influenza vaccination or disease
  • Receipt of any vaccine other than Hepatitis B prior to enrollment
  • Acute illness with rectal temperature >= 38.0 (defer enrollment)
  • Known bleeding disorder
  • Participation in other interventional clinical trial within 30 days prior to enrollment

Location and Contact Information

Please refer to this study by identifier  NCT00242424

Fred Ruben, MD      570-839-5633
Diane Maus, RN      570-839-4498

      Seattle Children''''s Hospital and Regional Medical Center, Seattle,  Washington,  98105,  United States
Janet A Englund, MD  206-987-2239 
Diane Kinnunen, RN  206-987-2205 
Emmanuel B Walter, MD, MPH,  Principal Investigator

Study chairs or principal investigators

Janet A Englund, MD,  Study Chair,  Children''''s Hospital and Regional Medical Center, Seattle, WA   

More Information

Study ID Numbers:  05065501
Last Updated:  December 8, 2005
Record first received:  October 19, 2005 Identifier:  NCT00242424
Health Authority: United States: Food and Drug Administration processed this record on 2006-01-10


Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us